CME: Ulcerative Colitis: Updates from the DDW 2019 Annual Meeting
ACCREDITATION EXPIRED: September 23, 2021
Activity Description / Statement of Need:
In this online, self-learning activity:
IBD is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are ulcerative colitis (UC) and Crohn’s disease, the former of which exclusively affects the colon and rectum. Guidelines exist for the treatment of UC, but they are constantly changing to include updated information. Despite the plethora of guidelines available, there are issues surrounding guideline adherence by physicians, patient satisfaction, the quality of treatment and a patient’s QOL. Given the data from multiple studies that physicians are either not aware of updated practice guidelines or are not utilizing them, that this lack of knowledge is affecting patient satisfaction, and that there may be demographically-based barriers to care, educational activities are warranted to keep HCPs abreast of best practices in patients with UC. This activity has been designed to review treatment strategies, emerging therapies, and gaps in care of patients with UC.
This activity is a learning activity focused on Ulcerative Colitis and its complications, designed to bring healthcare providers up to date in their practice and give them a sense of coming changes to practice and the literature.
Target Audience:
Healthcare professionals specializing in: gastroenterology, internal medicine, and those who otherwise commonly care for patients with UC.
This activity is supported by an educational grant from Salix / Bausch Health.
Learners may participate in this activity free of charge.
Release Date: September 23, 2019 -- Expiration Date: September 23, 2021
Faculty: Berkeley Limketkai, M.D., Ph.D.
Agenda
|
Faculty member introduction, disclosures, overview of Ulcerative Colitis |
|
Major findings from DDW 2019, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content) |
|
Predicted of applicability to clinical practice and patient cases, where relevant |
|
Concluding remarks |
Learning Objectives
By the end of the session the participant will be able to:
- Describe long-term outcomes of UC patients with dysplasia who undergo endoscopic resection and surveillance and apply that information to a patient case
- Describe the effect of endoscopic and histologic remission as treatment targets
- Describe the risk of biologic therapy use in special populations, such as elderly and surgical patients and apply that information to a patient case
- Recall emerging data on biologic drug safety and efficacy
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Berkeley N. Limketkai, M.D., Ph.D. , has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 0% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Ulcerative Colitis (UC): Optimizing Pharmacotherapeutic Management Strategies
Pediatric Crohn's disease: Therapeutic updates and optimizing treatment
Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?
Short bowel syndrome: therapeutic updates and optimizing treatment